A pharmaceutical composition and method for treating brain cancer are provided. The method includes administering to a patient in need thereof an effective amount of one or more compounds that include moclobemide, clorgyline, clorgyline's Near-infra-red dye Monoamine Oxidase Inhibitor (NMI), and MHI 148-clorgyline, and their salt thereof. The composition and method are particularly effective in reducing the size of glioblastomas that are temozolomide (TMZ) resistant.

The invention relates to indole carboxamide derivatives of formula (I), ##STR00001##
wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.10 and n are as defined in the description, their preparation and their use as pharmaceutically active compounds.

The invention relates to indole carboxamide derivatives of formula (I), ##STR00001##
wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.10 and n are as defined in the description, their preparation and their use as pharmaceutically active compounds.

Provided herein are small molecules comprising a first domain that binds to ASH1L and a second domain that facilitates ASH1L degradation. In particular, ASH1L-targeting proteolysis targeting chimeras (PROTACs) and methods of use thereof for the treatment of disease (e.g., acute leukemia, solid cancers and other diseases dependent on activity of ASH1L) are provided.

Provided herein are small molecules comprising a first domain that binds to ASH1L and a second domain that facilitates ASH1L degradation. In particular, ASH1L-targeting proteolysis targeting chimeras (PROTACs) and methods of use thereof for the treatment of disease (e.g., acute leukemia, solid cancers and other diseases dependent on activity of ASH1L) are provided.

A platform drug delivery system and a method of improving the delivery of low solubility pharmaceuticals utilizing crystal engineering and Theanine dissolution resulting in enhanced bioactivity, dissolution rate, and solid state stability.

A platform drug delivery system and a method of improving the delivery of low solubility pharmaceuticals utilizing crystal engineering and Theanine dissolution resulting in enhanced bioactivity, dissolution rate, and solid state stability.

The present application in one embodiment provides a compound of Formula (I) ##STR00001## or a pharmaceutically acceptable salt thereof, wherein X.sup.1, X.sub.2, X.sub.3, X.sub.4, X.sup.5, X.sup.6, Y.sup.1, Y.sup.2, Y.sup.3, R.sup.7, R.sup.8, R.sup.9, R.sup.10, R.sup.A, R.sup.B, W and Cy.sup.1 are as described herein. Pharmaceutical compositions containing these compounds, and methods of using these compounds for treating cancer, autoimmune diseases, and inflammatory diseases are also provided.

The present application in one embodiment provides a compound of Formula (I) ##STR00001## or a pharmaceutically acceptable salt thereof, wherein X.sup.1, X.sub.2, X.sub.3, X.sub.4, X.sup.5, X.sup.6, Y.sup.1, Y.sup.2, Y.sup.3, R.sup.7, R.sup.8, R.sup.9, R.sup.10, R.sup.A, R.sup.B, W and Cy.sup.1 are as described herein. Pharmaceutical compositions containing these compounds, and methods of using these compounds for treating cancer, autoimmune diseases, and inflammatory diseases are also provided.

Among other things, the present disclosure provides compounds, e.g., of formula I or salts thereof. In some embodiments, the present disclosure provides methods for modulating MRGPRX4 activity. In some embodiments, the present disclosure provides methods for preventing or treating conditions, disorders or diseases, e.g., MRGPRX4-associated conditions, disorders or diseases.